Description

Tempus AI Is Unlocking A New Era Of Oncology Intelligence Through Its Massive Clinical Data Network!

Tempus AI reported financial results for the fourth quarter and full year 2025. The company highlighted significant achievements, indicating a robust performance across both its core businesses, diagnostics and data. Tempus’ total revenue surged over 33%, particularly bolstered by the acquisition of Ambry. In the Diagnostics segment, their Oncology business experienced a 29% unit growth, with notable acceleration throughout the year. The Minimal Residual Disease (MRD) sector showcased exceptional growth, increasing by 56% quarter-over-quarter. Additionally, their Hereditary line saw a 23% rise in units. This strong performance underpins the company’s expanding market presence and increasing demand for its diagnostic solutions. The Data segment displayed even more significant traction, with the licensing business experiencing a 69% increase when including the one-time impact of the AstraZeneca warrant. Tempus projected this business to grow approximately 40% in the next quarter. The total contract value exceeded $1.